These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36851606)

  • 1. Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?
    Chu KB; Quan FS
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.
    Kim C; Kim JD; Seo SU
    J Microbiol; 2022 Mar; 60(3):335-346. PubMed ID: 35089583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of virus-like particle vaccines against respiratory viruses.
    Quan FS; Basak S; Chu KB; Kim SS; Kang SM
    Expert Rev Vaccines; 2020 Jan; 19(1):11-24. PubMed ID: 31903811
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of virus-like particles-based vaccines against coronaviruses.
    Yong CY; Liew WPP; Ong HK; Poh CL
    Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in virus-like particle-based SARS-CoV-2 vaccines.
    Hao X; Yuan F; Yao X
    Front Cell Infect Microbiol; 2024; 14():1406091. PubMed ID: 38988812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.
    Hemmati F; Hemmati-Dinarvand M; Karimzade M; Rutkowska D; Eskandari MH; Khanizadeh S; Afsharifar A
    Biotechnol Lett; 2022 Jan; 44(1):45-57. PubMed ID: 34837582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.
    Kim AR; Lee DH; Lee SH; Rubino I; Choi HJ; Quan FS
    PLoS One; 2018; 13(1):e0191277. PubMed ID: 29338045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Prosper P; Rodríguez Puertas R; Guérin DMA; Branda MM
    Vaccine; 2024 Jul; 42(18):3916-3929. PubMed ID: 38782665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
    Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
    Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
    Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
    J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.
    Chu KB; Quan FS
    Curr Top Microbiol Immunol; 2021; 433():77-106. PubMed ID: 33650036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.